Retina/Vitreous

Top Story

ONL Therapeutics receives approximately $1 million grant from NEI

March 23, 2017

The National Eye Institute has awarded ONL Therapeutics a grant worth almost $1 million to continue developing its lead therapeutic candidate ONL1204, according to a company press release.

ONL1204 is a small molecule FAS inhibitor designed to protect retinal cells, including photoreceptors, from cell death that occurs in multiple retinal diseases.

PUBLICATION EXCLUSIVE: ASCRS Research Council aims to mirror success of DRCR.net

March 22, 2017
The Diabetic Retinopathy Clinical Research Network is a collaboration among the National Eye Institute, the National Institute of Diabetes and Digestive and Kidney…

Phase 1/2 trial of gene therapy treatment for X-linked retinitis pigmentosa begins

March 22, 2017
A phase 1/2 clinical trial of a gene therapy treatment for X-linked retinitis pigmentosa has begun enrolling and dosing subjects, NightstaRx announced in a press…
Publication Exclusive

PUBLICATION EXCLUSIVE: Woman presents with cloudy declining vision and flashes

March 20, 2017
A 56-year-old Caucasian woman presented with painless, slowly decreasing “murky” vision in the left eye over a period of 3 weeks, along with flashes. Her…
Experimental Science

Therapeutic Window of Retinal Photocoagulation With Green (532-nm) and Yellow (577-nm) Lasers

Ophthalmic Surgery, Lasers and Imaging Retina, July 2012, Volume 43 Issue 4
The 577-nm (yellow) laser provides an alternative to the 532-nm (green) laser in retinal photocoagulation, with…
More »
CME

Wet Macular Degeneration: A Review of Pivotal Clinical Trials

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Featured
World Retina Congress

World Retina Congress

Video
Meeting News

VIDEO: The economic model for retinopathy of prematurity (EcROP)

January 27, 2017
More »

ONL Therapeutics receives approximately $1 million grant from NEI

March 23, 2017
The National Eye Institute has awarded ONL Therapeutics a grant worth almost $1 million to continue developing its lead therapeutic candidate…

PUBLICATION EXCLUSIVE: ASCRS Research Council aims to mirror success of DRCR.net

March 22, 2017
The Diabetic Retinopathy Clinical Research Network is a collaboration among the National Eye Institute, the National Institute of Diabetes and…

Phase 1/2 trial of gene therapy treatment for X-linked retinitis pigmentosa begins

March 22, 2017
A phase 1/2 clinical trial of a gene therapy treatment for X-linked retinitis pigmentosa has begun enrolling and dosing subjects, NightstaRx…

Publication Exclusive

PUBLICATION EXCLUSIVE: Woman presents with cloudy declining vision and flashes

March 20, 2017
A 56-year-old Caucasian woman presented with painless, slowly decreasing “murky” vision in the left eye over a period of 3 weeks, along…

Blog

BLOG: Advancements in devices that promote diagnosis and management of retinal disorders

March 17, 2017
New advancements in devices and technology are constantly improving our ability to more accurately diagnose issues and prescribe appropriate…

Study highlights potential of alternative anti-inflammatory agent

March 17, 2017
A single postoperative injection of XG-102 was non-inferior to dexamethasone eye drops in the management of surgery-induced ocular inflammation in a…

Serious health threats possible with underregulated commercial stem cell clinics

March 16, 2017
Stem cells hold potential benefits for the treatment of age-related macular degeneration, but commercial stem cell clinics that skirt under FDA…

In the Journals

Frequent anti-VEGF injections may be associated with increased risk of glaucoma surgery

March 16, 2017
A large pharmacoepidemiologic study carried out in British Columbia found that seven or more intravitreal injections of bevacizumab are associated…

Blog

BLOG: To fight diabetes, there's one question we should ask every patient

March 16, 2017
Diabetes has been called the disease that will bankrupt Medicare. As the single most expensive disease we treat, it reached more than $100 billion…

Lindstrom's Perspective

ASCRS Research Council aims to mirror success of DRCR.net

Ocular Surgery News U.S. Edition, March 25, 2017
Richard L. Lindstrom, MD
The Diabetic Retinopathy Clinical Research Network is a collaboration among the National Eye Institute, the National Institute of Diabetes and…

More Headlines »
Advertisement
Advertisement